218 related articles for article (PubMed ID: 23900343)
41. Characterizing binding of small molecules. II. Evaluating the potency of small molecules to combat resistance based on docking structures.
Ding B; Li N; Wang W
J Chem Inf Model; 2013 May; 53(5):1213-22. PubMed ID: 23570305
[TBL] [Abstract][Full Text] [Related]
42. Exploring QSARs for inhibitory activity of non-peptide HIV-1 protease inhibitors by GA-PLS and GA-SVM.
Deeb O; Goodarzi M
Chem Biol Drug Des; 2010 May; 75(5):506-14. PubMed ID: 20486937
[TBL] [Abstract][Full Text] [Related]
43. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
[TBL] [Abstract][Full Text] [Related]
44. Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease.
Fong P; McNamara JP; Hillier IH; Bryce RA
J Chem Inf Model; 2009 Apr; 49(4):913-24. PubMed ID: 19309119
[TBL] [Abstract][Full Text] [Related]
45. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
46. Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Shuman CF; Vrang L; Danielson UH
J Med Chem; 2004 Nov; 47(24):5953-61. PubMed ID: 15537350
[TBL] [Abstract][Full Text] [Related]
47. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
[TBL] [Abstract][Full Text] [Related]
48. Development of anti-HIV activity models of lysine sulfonamide analogs: a QSAR perspective.
Muthukumaran R; Sangeetha B; Amutha R; Mathur PP
Curr Comput Aided Drug Des; 2012 Mar; 8(1):70-82. PubMed ID: 21999609
[TBL] [Abstract][Full Text] [Related]
49. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J
J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738
[TBL] [Abstract][Full Text] [Related]
50. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
[TBL] [Abstract][Full Text] [Related]
51. Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases.
Sadiq SK; Wright DW; Kenway OA; Coveney PV
J Chem Inf Model; 2010 May; 50(5):890-905. PubMed ID: 20384328
[TBL] [Abstract][Full Text] [Related]
52. Characterization of New Cationic N,N-Dimethyl[70]fulleropyrrolidinium Iodide Derivatives as Potent HIV-1 Maturation Inhibitors.
Castro E; Martinez ZS; Seong CS; Cabrera-Espinoza A; Ruiz M; Hernandez Garcia A; Valdez F; Llano M; Echegoyen L
J Med Chem; 2016 Dec; 59(24):10963-10973. PubMed ID: 28002960
[TBL] [Abstract][Full Text] [Related]
53. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
54. Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study.
Ravichandran V; Mourya VK; Agrawal RK
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):288-94. PubMed ID: 20735159
[TBL] [Abstract][Full Text] [Related]
55. Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach.
Gupta P; Garg P; Roy N
Chem Biol Drug Des; 2012 May; 79(5):835-49. PubMed ID: 22233531
[TBL] [Abstract][Full Text] [Related]
56. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
57. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
[TBL] [Abstract][Full Text] [Related]
58. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
[TBL] [Abstract][Full Text] [Related]
59. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
60. The inhibition effect of garlic-derived compounds on human immunodeficiency virus type 1 and saquinavir.
Gökalp F
J Biochem Mol Toxicol; 2018 Nov; 32(11):e22215. PubMed ID: 30194790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
